Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard LITTLETON, Colo., October 21, 2026 — Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (Nasdaq: VVOS), a medical device and healthcare services company

Event · Listing notice
Exchange
The Nasdaq Stock Market LLC
Kind
regained compliance
Rule
Listing Rule 5550(b)(1)

Facts are quoted from the filing text and checked against it.

Original reporting
Published Oct 21, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 11:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$VVOS
Bullish
high confidence
Mentioned
$VVOS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$VVOSBullishLow
01

Why it matters

The letter removes a delisting threat, which could stabilize or slightly lift the share price.

02

Market read

Primary relevance is to VVOS shareholders; limited broader market effect.

03

What to watch

Potential dilution from conversion of the Series C preferred could offset equity gains if cap is lifted.

Relevance 6/10Novelty 6/10Timing: today

Background

The filing is a standard 8‑K Item 8.01 disclosure of a Nasdaq compliance letter after a recent equity transaction.

Company-level read

Ticker impact

$VVOSBullishHigh confidence
Context

Vivos Therapeutics disclosed receipt of a Nasdaq compliance letter confirming it meets the $2.5M stockholders' equity requirement, removing immediate delisting risk.

Expected impact

likely modest upside as investors price in reduced delisting risk

Evidence & confidence

The filing is the first public confirmation of compliance; no new financing or earnings data, but the risk of delisting is eliminated.

Market effects

Minimal; confirms compliance for a niche medical‑device firm, no broader sector impact.

None

Low

Counterpoint

If the equity boost from the preferred stock issuance is over‑estimated, the compliance may be temporary.

Key entities

  • Vivos Therapeutics, Inc.

    Medical device and healthcare services company focused on obstructive sleep apnea.

  • Nasdaq Stock Market LLC

    Issuer of the compliance letter confirming listing rule adherence.

Related articles

$VVOSHigh

A deal gives Vivos half of a test; reaching more than 325,000 patients still depends on agreements and court approval.

Vivos Therapeutics (VVOS) closed its acquisition of a 50% interest in a pseudohypoxia test and related intellectual property from SOD Sciences. The deal includes issuing 12,000 shares of Series C Convertible Preferred Stock, expected to increase stockholders’ equity by over $10 million. The companies plan to negotiate agreements to market products through new channels, potentially expanding Vivos' market reach to over 325,000 patients.

$VVOSHigh

Vivos Therapeutics, Inc. (VVOS): Completion of Acquisition or Disposition of Assets

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel Transaction Expected to Add More Than $10 Million to Stockholders’ Equity

$VVOSMed

Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants

Vivos Therapeutics (NASDAQ: VVOS) reported single-site clinical study results for its FDA-cleared Vida oral appliance in 37 adults with moderate-to-severe insomnia. All participants improved at least one Insomnia Severity Index category; average ISI fell ~65% and all ended as no clinically significant or subthreshold insomnia (p~1e-7). Vivos cites potential market expansion beyond OSA/COMISA.

$VVOSMed

Vivos, SPCVA Form AIM Florida To Expand Sleep Apnea And Insomnia Care For CVD Patients

Vivos Therapeutics (VVOS) said it will collaborate with South Palm Cardiovascular Associates (SPCVA) to form AIM Florida, LLC, a physician-aligned management services organization to expand integrated diagnosis and treatment for obstructive sleep apnea and insomnia in cardiovascular disease patients. Vivos expects to hold at least 80% of AIM Florida. The initial focus is Palm Beach County.